secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2024-08-30T23:59:59+00:00
Accession:  0001493152-24-034646
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PowerUp Acquisition Corp. enters into definitive merger agreement with Aspire Biopharma valued at $316.8M
--------------------------------------------------------------------------------

- Consideration to Aspire stockholders: shares of New Aspire Common Stock valued at $316.8M less indebtedness and cash shortfall.
- Post-closing board: 7 directors (2 from PowerUp, 5 from Aspire); CEO and CFO to be Aspire's current officers.
- Closing conditions include shareholder approvals, SEC effectiveness of Form S-4, Nasdaq listing, and no material adverse effects.
- No termination fees; outside date of August 17, 2025 to consummate the transaction.
- PowerUp will domesticate from Cayman Islands to Delaware prior to closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315224034646/0001493152-24-034646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315224034646/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-034646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer